Petersen LC. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.
Summary. Background: Initiation of coagulation is induced by binding of activated factor VII (FVIIa) to tissue factor (TF) and activation of factor X (FX) in a process regulated by tissue factor pathway inhibitor (TFPI). TFPI contains three Kunitz-type protease inhibitor domains (K1-K3), of which K1 and K2 block the active sites of FVIIa and FXa, respectively. Objective: To produce a monoclonal antibody (mAb) directed towards K1, to characterize the binding epitope, and to study its effect on TFPI inhibition. Methods: A monoclonal antibody, mAb2F22, was raised against the N-terminal TFPI fragment. Binding data were obtained by surface plasmon resonance analysis. The Fab-fragment of mAb2F22, Fab2F22, was expressed and the structure of its complex with TFPI(1-79) determined by X-ray crystallography. Effects of mAb2F22 on TFPI inhibition were measured in buffer-and plasma-based systems. Results: mAb2F22 bound exclusively to K1 of TFPI (K D~1 nM) and not to K2. The crystal structure of Fab2F22/TFPI (1-79) mapped an epitope on K1 including seven residues upstream of the domain. TFPI inhibition of TF/FVIIa amidolytic activity was neutralized by mAb2F22, although the binding epitope on K1 did not include the P1 residue. Binding of mAb2F22 to K1 blocked TFPI inhibition of the FXa amidolytic activity and normalized hemostasis in hemophilia human A-like plasma and whole blood. Conclusion: mAb2F22 blocked TFPI inhibition of both FVIIa and FXa activities and mapped a FXa exosite for binding to K1. It reversed TFPI feedback inhibition of TF/FVIIa-induced coagulation and restored clot formation in FVIII-neutralized human plasma and blood.
Introduction
Injury of the vessel wall exposes tissue factor (TF) to the circulating blood and initiates hemostasis when factor VII (FVII) binds to TF and is activated to FVIIa. The resulting FVIIa/TF complex activates factors IX and X (FIX and FX) to FIXa and FXa [1] [2] [3] , which induces a propagation reaction involving FVIII and FIX, resulting in thrombin-mediated fibrin deposition [4, 5] . Tissue factor pathway inhibitor (TFPI) is the central regulator of TF/ FVIIa-initiated coagulation [6] [7] [8] . Two main splice variants, TFPIa (referred as TFPI) and TFPIb, are transcribed. TFPI comprises 276 amino acids, and it contains an acidic N-terminal region, three Kunitz-type protease inhibitor (K1-3) domains and a C-terminal basic region. TFPIb comprises 223 amino acids. It shares the first 181 amino acids, including K1 and K2, with TFPI. The C-terminal of TFPIb contains a glycosyl-phosphatidyl inositol (GPI) attachment signal that localizes it to the cell membrane. In contrast, the C-terminal of TFPI designates it to be secreted or non-covalently attached to the cell membrane [9, 10] . K1 interacts with the active site of FVIIa, and TFPI at high concentrations can inhibit TF/FVIIa, although in the presence of protein S or FXa the K i of TF/FVIIa inhibition is reduced [11, 12] . K2 interacts with the active site of FXa, and TFPI at low concentrations can inhibit FXa in a process described by the formation of a loose encounter FXa/TFPI complex, which subsequently slowly isomerizes to a tight FXa/ TFPI complex [13] .
Hemophilia is a bleeding disorder caused by inherited or acquired deficiency of either FVIII (hemophilia A) or FIX (hemophilia B). Supplement with recombinant FVIII or FIX proteins is a common therapy applied to hemophilia patients. However, development of inhibitory antibodies (inhibitors) against FVIII or FIX in a number of hemophilia patients provides a challenge to replacement therapy. Recombinant FVIIa has been successfully applied as a bypassing agent for treatment of these inhibitor patients [14] . Prevention of TFPI inhibition promotes and prolongs TF/FVIIa-mediated FXa generation sufficiently to restore coagulation in hemophilia patients [15] [16] [17] [18] . Blockage of TFPI inhibition may be obtained by interfering with several specific protein-protein interactions. This is indicated by results showing a strongly decreased inhibition by separate Kunitz domains [11, 19] and by protease cleaved TFPI [20, 21] , just as blockage of TFPI inhibition has been obtained by binding of mAbs, small peptides or aptamers to various regions of TFPI [17, 22, 23] . These observations suggest that the overall stability of the TF/FVIIa/FXa/TFPI complex is dominated by strong interactions with exosites on TFPI rather than the relatively weak interactions between the primary contact areas of K1 and K2 domains and the corresponding substrate binding sites of FVIIa and FXa. The present work describes the effects of a monoclonal antibody, mAb2F22, which binds to an epitope on the K1 domain does not directly cover residue of this domain. Even so, mAb2F22 reverses the inhibition by TFPI of both FVIIa and FXa and also works to promote coagulation in hemophilia A plasma and whole blood.
Materials and methods

Reagents
Recombinant human FVIIa (NovoSeven Ò ) was from Novo Nordisk (Bagsvaerd, Denmark). Lipidated TF was from Siemens, (Munich, Germany) (Innovin Ò ) or prepared in-house using TF(1-244), expressed in E. coli and lipidated with 25:75 phosphatidylserine/phosphatidylcholine as previously described [24] . S2288 and S2765 were from Chromogenix (Instrumentation Laboratory, Bedford, MA, USA). Spectrozyme FIXa was from American Diagnostica (Troy, MI, USA). Human FX and FXa were from Enzyme Research Laboratories (South Bend, IN, USA). Human FIX and phospholipids (25:75 phosphatidylserine/phosphatidylcholine) were from Haematologic Technologies, Inc. (Essex Junction, VT, USA). Tick anticoagulant peptide (TAP) was expressed in E. coli. Human recombinant TFPI, TFPI(1-267), was produced as previously described [17] . TFPI(1-161), TFPI(1-79) and TFPI(91-150) were expressed in E. coli. with N-terminal composite tags for TFPI(1-161): His 6 -NusA-HRV3C-His 6 -(Gly 1 Ser 2 ) 2 Gly and for TFPI(1-79): TrxA-His 6 -(Gly 1 Ser 2 ) 2 Gly-HRV3C, or a C-terminal tag for TFPI(91-150): His 6 . The fusion proteins TFPI(1-79) and TFPI(1-161) were expressed in and isolated from the soluble fraction. TFPI(91-150) was captured by IMAC from the periplasmic fraction and purified by IEXC. N-terminally tagged fragments were enzymatically processed by HRV 3C and polished by size-exclusion chromatography. Immunization and screening RBF mice were immunized with TFPI or TFPI (1-161) in the presence of Freund's adjuvant. Eye-blood from immunized mice was screened after 10 days by ELISA for TFPIspecific antibodies. The mice were then boosted with human TFPI or TFPI (1-161) and sacrificed after 3 days. Spleen and myeloma cells were fused using standard polyethylene glycol (PEG) or electrofusion. Hybridomas positive for TFPI(1-161) binding and negative for TFPI (91-150) binding were selected by ELISA and used for antibody production. Antibodies were purified from supernatants by standard protein-A affinity chromatography and screened by ELISA for TFPI binding. Functional screening was performed, measuring the effect on TFPI inhibition of TF/FVIIa-mediated FX activation.
Cloning, expression and purification of Fab2F22
Coding sequences spanning the V H and V L regions of the murine anti-TFPI antibody, mAb2F22, were amplified from hybridoma cell RNA using the SMART TM RACE cDNA amplification kit (Clontech, Takara Bio Inc., Kusatsu, Japan). For recombinant expression of a mouse/ human chimeric Fab fragment of the antibody, the mAb2F22 variable regions were PCR amplified and cloned into toolbox vectors carrying a human kappa light chain C L for the V L fragment. The V H fragment was cloned into a toolbox vector carrying a human IgG4 C H truncated after the hinge lysine. The anti-TFPI Fab fragment was expressed transiently in EXPI293F cells (Life Technologies, Carlsbad, CA, USA), by co-transfection of the LC and HC expression vectors according to the manufacturer's instructions. Fab2F22 was purified from cell culture supernatants using a KappaSelect affinity column (GE Healthcare, Chicago, IL, USA), followed by size-exclusion chromatography on a Superdex75 column (GE Healthcare).
X-ray crystallography and modelling A 1 : 1 molar complex of TFPI(1-79) and Fab 2F22 was crystallized by the hanging-drop method using a precipitant solution of 20% w/v PEG 3350 and 200 mM potassium formate. The TFPI(1-79)/Fab2F22 complex structure was refined with data to 1.65 A resolution, and the crystal coordinates of the complex deposited in the Protein Data Bank with the accession code 5NMV.
Potential interference between simultaneous binding of Fab2F22 and FVIIa to TFPI K1 was assessed by superimposing the crystal structure of a FVIIa/sTF/BPTImutant complex [25] , Protein Data Bank [26] code 1FAK, with the Fab2F22/TFPI(1-79) complex structure based on 252 main-chain atoms of bovine pancreatic trypsin inhibitor (BPTI) and TFPI(1-79), respectively (root-mean-square 0.606 A). The PyMol software [27] was used for superimposition.
Binding of mAb2F22 to TFPI
Binding interaction analysis was conducted by surface plasmon resonance (SPR) using a Biacore T100 instrument (GE Healthcare). Capture of antibodies from hybridoma supernatants was achieved with an immobilized antibody against the murine Fc region (GE Healthcare). Purified antibodies were directly immobilized by amine coupling to a CM5 chip (GE Healthcare). Binding to the immobilized antibody of TFPI, TFPI(1-161), TFPI(1-79) or TFPI(93-150) was measured using 2-fold dilution series ranging from 200 nM to 0.05 nM. Kinetics (association rate constant [k a ] and dissociation rate constant [k d ]) and binding
were determined assuming a 1 : 1 interaction of TFPI and mAb2F22, using the Biacore evaluation software (GE Healthcare). To measure binding of mAb2F22 to a preformed FXa/TFPI complex, FXa was captured on an anti-GLA domain FX antibody directly immobilized to a CM4 sensorchip (GE Healthcare) using amine coupling. Afterwards, TFPI was captured on FXa and binding of 50 nM mAb2F22, Fab2F22 or anti-TFPI K2 mAb2021 to TFPI/FXa/anti-FXa mAb was monitored.
Effects of mAb2F22 on the inhibition by TFPI of TF/FVIIa activity and on the TFPI/TF/FVIIa complex TF/FVIIa amidolytic activity was measured with 5 nM FVIIa and 10 nM TF (Innovin) in the presence of 2 mM S2288 in 50 mM HEPES, 100 mM NaCl, 5 mM CaCl 2 , 0.1% BSA, pH 7.3 (HNBSACa); 100 nM TFPI was incubated with/without 100 nM mAb2F22 for 30 min prior to addition of S2288 and TF/FVIIa. For experiments with a preformed TFPI/TF/FVIIa complex, TFPI was incubated with TF/FVIIa for 15 min prior to addition of S2288 followed by 15 min incubation before addition of mAb2F22. TF/FVIIa mediated FIX activation was measured with 50 pM FVIIa, 5 nM TF (Innovin) and 200 nM FIX in the presence of 0.5 mM Spectrozyme FIXa in 50 mM HEPES, 150 mM NaCl, 10 mM CaCl 2 , 0.1% BSA, 0.1% PEG8000, pH 7.3 (HNBSACaPEG). TFPI was incubated with/without mAb2F22 for 5 min prior to addition of FVIIa/TF, followed by 7 min incubation at 37°C before addition of Spectrozyme FIXa and FIX. From the progress curves of FIX activation, rates of FIX activation (first derivative of the progress curves) were calculated. From the rates of FIX activation, the percentage inhibition of FVIIa/TF was calculated and plotted as function of TFPI concentration and fitted to the Langmuir binding isotherm as previously described [28] . Chromogenic substrate conversion was measured at 405 nm in a Spectramax reader.
Effects of mAb2F22 on the inhibition of FXa amidolytic activity by TFPI and on the stable TFPI/FXa complex TFPI (0-20 nM) was incubated in HNBSACa with/without 100 nM mAb2F22 for 30 min, followed by addition of 0.5 mM S2765 and 0.1 nM FXa.
Progress curves of FXa inhibition by TFPI in the absence of mAb2F22 were fitted to the integrated rate equation for slow-tight binding inhibition [13] . Progress curves of FXa inhibition by TFPI in the presence of mAb2F22 were fitted to a straight line. The v 0 and v s were used to calculate the K i and the K i *:
where Y is v 0 or v s , v is the maximum velocity, S is substrate concentration of S2765 (0.5 mM), K m is MichaelisMenten constant for S2765 substrate cleavage by FXa (determined to 70 lM, data not shown) and x is concentration of TFPI.
For experiments with a preformed TFPI/FXa complex, 2 nM TFPI was incubated with 0.5 nM FXa for 15 min prior to addition of S2765, followed by 15 min incubation before addition of 50 nM mAb2F22. Chromogenic substrate conversion was followed at 405 nm in a Spectramax reader.
Effect of mAb2F22 on the inhibition by TFPI of TF/FVIIa in the presence of FXa TF/FVIIa amidolytic activity in the presence of 20 nM FXa was measured with 5 nM FVIIa and 10 nM TF (Innovin) in the presence of 0.8 mM S2288 in HNBSACa-PEG. TFPI (0-20 nM) was incubated with/without 10 nM mAb2F22 for 5 min prior to addition of FVIIa, TF and FXa. After 30 min incubation, the remaining FVIIa activity was measured at 405 nm in a Spectramax reader with S2288 in the presence of 1 lM TAP. K d (K i ) values were obtained by fitting data by nonlinear least squares regression analysis [29] .
Effect of mAb2F22 on the TF/FVIIa/FXa/TFPI complex TF/FVIIa or FXa amidolytic activity in the presence of 0.5 nM FXa was measured with 5 nM FVIIa and 10 nM TF in the presence of 0.8 mM S2288 in the presence of 1 lM TAP or 2 mM S2765 respectively in HNBSACaPEG. 2 nM TFPI was incubated with TF/FVIIa/FXa for 15 min prior to addition of S2288 or S2765, followed by 15 min incubation before addition of 50 nM mAb2F22. Chromogenic substrate conversion was followed at 405 nm in a Spectramax reader.
Effect of mAb2F22 on the inhibition by TFPI of TF/FVIIamediated FX activation
The effect of mAb2F22 on TFPI inhibition of TF/FVIIa mediated FXa generation, was measured by incubating TFPI (1.5 nM) with mAb2F22 (0-60 nM) for 5 min in HNBSACaPEG. FX (160 nM) was added and the reaction was initiated by addition of TF (Innovin, 10 pM) and FVIIa (0.5 nM). The activity was quenched after 15 min by addition of EDTA (20 mM) and FXa activity with S2765 (0.5 mM) was measured at 405 nm in a Spectramax reader and calibrated against FXa activity standard curve.
Thrombin generation
The effect of mAb2F22 on thrombin generation was measured in citrate-stabilized normal plasma (Precision Biologics, Rockville, MD, USA) or FVIII immune-depleted plasma (Dade Behring) supplemented with 10 lM phospholipids; or it was measured in FVIII-depleted plasma with addition of TFPI or TFPI(1-161) (0-20 nM). Coagulation was initiated by re-calcification and addition of TF (Innovin). Thrombin activity was assessed by calibrated automated thrombin generation measurements [30] .
Thromboelastography Thromboelastography (TEG) experiments were conducted with citrate-stabilized blood from four male donors. Blood was incubated with sheep anti-FVIII IgG (Hematologic Technologies). TF (Innovin 0.03 pM), mAb2F22 and blood were added to the TEG cup containing calcium, and the TEG analysis was immediately initiated.
Results
Selection of an anti-TFPI antibody, mAb2F22
A murine antibody capable of neutralizing TFPI inhibition of TF/FVIIa-mediated FX activation was selected from hybridoma clones and denoted mAb2F22. SPR analysis showed that mAb2F22 binds to TFPI with a sub-nanomolar affinity (K D = 0.7 nM) characterized by the following on rate and off rate: ). In contrast, no detectable response was obtained for mAb2F22 binding to K2 (TFPI(93-150) ). Collectively, the data suggest a binding epitope for mAb2F22 located exclusively within the N-terminal residues 1-79.
The epitope for mAb2F22 binding comprises K1 residues and residues upstream of this domain TFPI(1-79) and Fab2F22 were co-crystallized and the structure solved by X-ray crystallography to obtain a more detailed mapping of the interaction between mAb2F22 and TFPI in the complex (Fig. 1A and Table 1 ). The Fab2F22 was found to engage an epitope comprising residues of the K1 domain (C35, A37, M39, R41, Y56, G57, G58, C59, E60, G61, N62, Q63, R65, F66, E67, E71 and M75) and also a few residues upstream of the domain (L16, P17, L19, L20, L21, M22 and F25). Based on structural considerations, the epitope residues R41, R65 and E67 appear to be of particular importance for the interaction. The epitope does not include K36, the P1 residue of K1 [31] , although mAb2F22 neutralizes TFPI inhibition of TF/FVIIa (see below).
Effects of mAb2F22 on the interactions between TFPI and TF/FVIIa
In agreement with the published K i values, high nanomolar TFPI concentrations were required for inhibition of TF/FVIIa amidolytic activity [11, 12] . Partial abrogation of inhibition at 100 nM TFPI was obtained with 100 nM mAb2F22 ( Fig. 2A) . The data demonstrated that the P1 residue (K36) of TFPI, essential for blocking of the active site of TF/FVIIa by K1 of TFPI, was displaced by the antibody, although the mAb2F22 binding epitope does not include K36. Figure 1 illustrates that the K1 interaction with FVIIa may be sterically prevented by collision with the bulky V H region of mAb2F22. Figure 2 (B) shows that addition of mAb2F22 to a preformed TF/FVIIa/TFPI complex increased the FVIIa activity. Because K i for TFPI inhibition of TF/FVIIa is high, mAb2F22 may act by binding to unbound TFPI, pushing the equilibrium towards the free components, rather than displacing TFPI from TF/FVIIa.
The mAb2F22 antibody was also investigated for its ability to affect TFPI inhibition of FIX activation mediated by TF/FVIIa. High nanomolar TFPI concentrations were required for inhibition of TF/FVIIa-mediated FIXa generation ( Fig. 2C ; K i = 33.6 AE 11.1 nM) [28] . Partial abrogation of inhibition at 200 nM TFPI was obtained with 100 nM mAb2F22 (Fig. 2D) .
Combined, these data demonstrate that mAb2F22 affects TFPI inhibition of both the amidolytic and proteolytic activities of TF/FVIIa.
Effects of mAb2F22 on the interactions between TFPI and FXa
Inhibition of FXa by TFPI displayed a biphasic inhibition that can be described with a K i (24.9 AE 9.6 nM, obtained from v 0 ) and a K i * (0.4 AE 0.09 nM, obtained from v s ) (Fig. 3A, C) . Inhibition of FXa by TFPI in the presence of mAb2F22 displayed a monophasic inhibition where v s approached v 0 (Fig. 3B, C) and K i = 6.5 AE 0.4 nM. Figure 3(D) shows that addition of mAb2F22 to a preformed tight FXa/TFPI complex, where FXa activity is fully inhibited, resulted in release of FXa activity. Binding of mAb2F22 to a preformed FXa/TFPI complex could be measured in an SPR assay, suggesting the existence of a ternary FXa/TFPI/ mAb2F22 complex (Fig. 3E) . In contrast, the anti-K2 mAb2021 could not bind to the preformed complex. Because binding of mAb2F22 will be influenced by avidity in the assay set-up, Fab2F22 binding to FXa/TFPI was analyzed. During the dissociation phase the response dropped below the baseline, suggesting that binding of Fab2F22 to FXa/TFPI resulted in the dissociation of TFPI from FXa.
These data suggest that mAb2F22 reverses the tight FXa-TFPI* complex to a loose FXa-TFPI encounter complex and although the binding epitope does not encompass K2, mAb2F22 is capable of efficiently abrogating TFPI inhibition of FXa activity.
Effect of mAb2F22 on the interactions between TFPI and TF/FVIIa/FXa
The K i for TFPI inhibition of TF/FVIIa is remarkably lowered in the presence of FXa [12] . In agreement, we determined a K i of 0.8 AE 0.2 nM for TFPI inhibition of TF/FVIIa/FXa by measuring TF/FVIIa activity in the presence of the FXa inhibitor TAP (Fig. 4A, filled circles) . Pre-incubating TFPI with an excess of mAb2F22 increased the K i 6-fold to 4.8 AE 0.8 nM (Fig. 4A , open squares), but did not prevent TFPI inhibition of TF/ FVIIa/FXa.
Because mAb2F22 could rescue activity from both FXa/TFPI and TF/FVIIa/TFPI complexes, we measured whether mAb2F22 could rescue FXa or FVIIa activity from the ternary TF/FVIIa/FXa/TFPI complex. The effect of TF/FVIIa on the ability of mAb2F22 to displace FXa from TFPI was addressed by measuring FXa activity following addition of mAb2F22 to a pre-incubated mixture of TFPI/TF/FVIIa/FXa and S2765. Only a minor effect of mAb2F22 was observed, indicating that mAb2F22 is unable to displace FXa when in complex with FVIIa/TF/TFPI (Fig. 4B) . Likewise, the effect of FXa on the ability of mAb2F22 to release FVIIa activity was addressed by measuring FVIIa activity following addition of mAb2F22 to a pre-incubated mixture of TFPI/TF/FVIIa/FXa and S2288. No FVIIa activity could be measured under these conditions, indicating that mAb2F22 also is unable to displace FVIIa when in complex with TF/FXa/TFPI (Fig. 4C) .
Effect of mAb2F22 on the inhibition by TFPI of TF/FVIIamediated FX activation TF/FVIIa-mediated FX activation was completely inhibited by 1.5 nM TFPI (Fig. 4D, filled circles) and only a partial reversal of FXa inhibition was observed when TFPI was pre-incubated with mAb2F22. In contrast, inhibition of FXa by 1.5 nM TFPI(1-161) was essentially fully reversed by mAb2F22 (Fig. 4D, filled squares) .
Effect of mAb2F22 on TF/FVIIa-induced thrombin generation and clot formation
Reversal of TFPI inhibition by mAb2F22 was also evident from its procoagulant effect in plasma measured by a thrombin generation (TGT) assay. Figure 5(A) shows the thrombin generation pattern in normal plasma when coagulation is initiated by TF (0-1 pM), which was enhanced in the presence of 100 nM mAb2F22 (Fig. 5B ). Likewise, a procoagulant effect by mAb2F22 was observed in FVIIIdepleted plasma ( Fig. 5C and D) . The results suggest that the thrombin response is strongly dependent on the concentration of TF applied for initiation of coagulation, and also on the fact that TFPI is an important modulator of this response. The modulatory role of TFPI was further evaluated in a TGT experiment (Fig. 6 ) where FVIII-depleted plasma was supplemented with 100 nM mAb2F22 in the presence of TFPI (Fig. 6A) or TFPI(1-161) (Fig. 6B) . The results suggest that mAb2F22 more efficiently reversed TFPI inhibition at high concentrations of TFPI(1-161) than at high concentrations of TFPI. This and the results in Fig. 4 (D) are in accordance with previous results [23] suggesting that interactions with the C-terminal region of TFPI contribute significantly to its modulatory effect on TF-induced initiation of the coagulation. In addition, mAb2F22 shortened the clotting (R) time and increased the maximum thrombus generation (MTG) under hemophilia A-like conditions as measured by TEG in blood (Table 2) .
Discussion
The present work illustrates that blocking of TFPI inhibition can compensate for an inadequate coagulation caused by hemophilia. We showed that this can be achieved by binding of a monoclonal antibody to an epitope on K1, including seven residues upstream of K1 as shown in Fig. 1(A) . Another TFPI blocking K1 antagonist with a procoagulant effect has been described as a potential candidate for hemophilia treatment [22] . The procoagulant effect was obtained by binding a peptide (compound 3) to a site on K1 distinct from the mAb2F22 epitope with only A37 of TFPI in common. Still compound 3 appeared to induce similar effects as mAb2F22 on TFPI inhibition of TF/FVIIa activities (Fig. 2) and FXa activities (Fig. 3) , and like mAb2F22 it also promoted coagulation in normal and hemophilia A-like plasma and blood (Figs 5 and 6, Table 2 ). A common feature of the binding of both compounds to K1 is an apparent steric overlap with the putative FVIIa contact area. A model illustrating the apparent spatial overlap between FVIIa and mAb2F22 upon binding of both proteins to K1 is shown in Fig. 1(B) . The model is based on our crystal structure of the FAb2F22/TFPI(1-79) complex and the previously published crystal structure of TF/ FVIIa in complex with a BPTI mutant [25] . A similar direct interference with the docking of K2 into the active site of FXa does not appear a likely explanation for its antagonistic effect on inhibition of FXa by TFPI, because the binding affinity for mAb2F22 to TFPI was not improved by the presence of K2 and no binding to K2 could be detected. A more indirect mechanism appears to be involved (e.g. K1 may provide an exosite for FXa). The results are in line with data from Peraramelli et al., showing that K1 is required for isomerization of the loose to the tight FXa/TFPI complex [13] , and blocking TFPI with an antibody against K1 (mAb2F22) seems to generate effects similar to removing the K1 domain from TFPI.
The modulatory action of TFPI on the TF/FVIIamediated initiation of coagulation has an important regulatory function in ensuring an immediate, efficient and localized coagulation process upon injury of the blood vessel wall. This intricate function may explain the complexity of TFPI biology, with expression of TFPIa and TFPIb forms with different partitioning of TFPI in the circulation as soluble, cell-associated, cell-bound and lipoparticle-associated forms, just as the complex inhibitory feedback mechanism of TFPI reflects this aspect [10] . The direct inhibition of TF/FVIIa activity is weak but tightens considerably in the presence of protein S [12] and when FXa is generated. FXa forms a complex with TFPI that binds with high affinity to TF/FVIIa to form the inactive ternary TF/FVIIa/FXa/ TFPI complex. Extension of the initiation phase of TF/ FVIIa-mediated FX activation by blocking the TFPI inhibition of FXa therefore constitutes an attractive strategy for promotion of hemostasis in hemophilia treatment. 
Inhibition of FXa by TFPI is alone characterized by multiple interactions, as suggested by data showing that the affinity of the separate K2 domain for FXa was about three orders lower than that of TFPI [11] . Also, cleavage of TFPI between K1 and K2 dramatically reduced the affinity of TFPI for FXa [20, 21] . Furthermore, the carboxy-terminal domain of TFPI is required for rapid and efficient FXa inhibition [32] and for the interaction with protein S [33] .
All this suggests that the primary interaction between the active site of FXa and the contact area on K2 including the P1 residue (R107) is weak but strongly supported by exosite interactions and may account for findings showing that a procoagulant effect can be promoted by binding to various regions of TFPI. Even so, promotion of coagulation in hemophilia in in vitro and in vivo models has been possible by blockage of FXa inhibition by binding of an antibody, mAb2021, to the contact P1 area of the K2 domain, a concept currently being tested in clinical trials for hemophilia treatment [17, 18] . The present work and previous reports [22] have shown that K1 antagonists are efficient as blockers of FXa inhibition by TFPI and therefore candidates for hemophilia treatment. Although epitopes for mAb2F22 (Fig. 1A) and another K1 antagonist have been determined [22] , it is still not possible with certainty to deduce the exact nature of how K1 promotes the transition from a loose to a tight FXa/TFPI complex.
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